Basic Information

Professional Memberships

• From Mar. 2000, To Present

  THE JAPANESE SOCIETY OF HEMATOLOGY
• From May 1999, To Present

  THE JAPANESE SOCIETY OF INTERNAL MEDICINE
• From Aug. 2014, To Sep. 2019

  THE JAPANESE SOCIETY FOR IMMUNOLOGY
• From Mar. 2016, To Mar. 2019

  日本再生医療学会

Academic Degree

• 博士（医学）(京都大学)

Research History

• From Dec. 2024, To Present

  Kyoto University, iPS細胞研究所, 特定准教授

ID,URL

• ORCID ID

  0000-0002-7271-9175

• J-Global ID

  201601016572155134

• Researcher number

  10447956

researchmap URL

• https://researchmap.jp/7000015500

Research

Research Interests

• regenerative medicine
• immunology
• hematology

Research Areas

• Life sciences, Biomaterials, regenerative biomedical engineering
• Life sciences, Biomedical engineering, regenerative biomedical engineering
• Life sciences, Hematology and oncology, Transfusion medicine
• Life sciences, Hematology and oncology, Platelets
• Life sciences, Hematology and oncology, hemato-oncology
• Life sciences, Hematology and oncology, HEMATO-IMMUNOLOGY

Papers

• Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets

  Si Jing Chen; Naoshi Sugimoto; Koji Eto

  International Journal of Hematology, Mar. 2023, Peer-reviewed

  
• Stem cell-derived platelets

  Peter Karagiannis; Naoshi Sugimoto; Koji Eto

  Platelets, 01 Jan. 2019

  
• ゲノム編集技術を用いたiPS細胞由来特異的HPA発現パネル細胞株の開発 HPA-3a抗体の特異的な検出

  林 智也; 三島 優一; 中村 壮; 杉本 直志; 堀田 秋津; 正木 美香子; 田中 光信; 石井 博之; 立山 英美; 藤村 吉博; 平山 文也; 谷 慶彦; 木村 貴文; 江藤 浩之; 瀧原 義宏

  日本輸血細胞治療学会誌, Apr. 2023

  
• A let-7 microRNA-RALB axis links the immune properties of iPSC-derived megakaryocytes with platelet producibility

  Si Jing Chen; Kazuya Hashimoto; Kosuke Fujio; Karin Hayashi; Sudip Kumar Paul; Akinori Yuzuriha; Wei-Yin Qiu; Emiri Nakamura; Maria Alejandra Kanashiro; Mio Kabata; Sou Nakamura; Naoshi Sugimoto; Atsushi Kaneda; Takuya Yamamoto; Hirohide Saito; Naoya Takayama; Koji Eto

  Nature Communications, 22 Mar. 2024

  Access this paper :

  
• Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells.

  Charlotte Flahou; Tatsuya Morishima; Natsumi Higashi; Yoshikazu Hayashi; Huaigeng Xu; Bo Wang; Chaoqi Zhang; Atsushi Ninomiya; Wei-Yin Qiu; Akinori Yuzuriha; Daisuke Suzuki; Sou Nakamura; Markus Manz; Shin Kaneko; Akitsu Hotta; Hitoshi Takizawa; Koji Eto; Naoshi Sugimoto

  Biochemical and biophysical research communications, 20 Apr. 2023

  
• Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial.

  Naoshi Sugimoto; Sou Nakamura; Shin Shimizu; Akiko Shigemasa; Junya Kanda; Nobuki Matsuyama; Mitsunobu Tanaka; Tomoya Hayashi; Akihiro Fuchizaki; Masayuki Nogawa; Naohide Watanabe; Shinichiro Okamoto; Makoto Handa; Akira Sawaguchi; Dai Momose; Ki-Ryang Koh; Yoshihiko Tani; Akifumi Takaori-Kondo; Koji Eto

  Blood advances, 23 Sep. 2022

  Access this paper :

  
• iPLAT1: The first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study.

  Naoshi Sugimoto; Junya Kanda; Sou Nakamura; Toshiyuki Kitano; Masakatsu Hishizawa; Tadakazu Kondo; Shin Shimizu; Akiko Shigemasa; Hideyo Hirai; Yasuyuki Arai; Manabu Minami; Harue Tada; Dai Momose; Ki-Ryang Koh; Masayuki Nogawa; Naohide Watanabe; Shinichiro Okamoto; Makoto Handa; Akira Sawaguchi; Nobuki Matsuyama; Mitsunobu Tanaka; Tomoya Hayashi; Akihiro Fuchizaki; Yoshihiko Tani; Akifumi Takaori-Kondo; Koji Eto

  Blood, 16 Sep. 2022

  
• Silencing of p53 and CDKN1A establishes sustainable immortalized megakaryocyte progenitor cells from human iPSCs

  Masamitsu Sone; Sou Nakamura; Sachiko Umeda; Harumi Ginya; Motohiko Oshima; Maria Alejandra Kanashiro; Sudip Kumar Paul; Kanae Hashimoto; Emiri Nakamura; Yasuo Harada; Kyoko Tsujimura; Atsunori Saraya; Tomoyuki Yamaguchi; Naoshi Sugimoto; Akira Sawaguchi; Atsushi Iwama; Koji Eto; Naoya Takayama

  Stem Cell Reports, Dec. 2021

  Access this paper :

  
• Extracellular laminin regulates hematopoietic potential of pluripotent stem cells through integrin β1-ILK-β-catenin-JUN axis.

  Akinori Yuzuriha; Sou Nakamura; Naoshi Sugimoto; Shunsuke Kihara; Masato Nakagawa; Takuya Yamamoto; Kiyotoshi Sekiguchi; Koji Eto

  Stem cell research, May 2021

  Access this paper :

  
• Generation and manipulation of human iPSC-derived platelets.

  Naoshi Sugimoto; Koji Eto

  Cellular and molecular life sciences : CMLS, Apr. 2021

  
• Dual fungal infection with Lomentospora prolificans and Aspergillus fumigatus: A pathogenetic diagnosis elucidated after two decades by sequential examinations.

  Yoshitsugu Sugiura; Naoshi Sugimoto; Takayuki Takahashi; Tadahiko Matsumoto

  Clinical case reports, Mar. 2021

  Access this paper :

  
• Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies.

  Ryo Ishino; Yumi Kawase; Toshio Kitawaki; Naoshi Sugimoto; Maki Oku; Shumpei Uchida; Osamu Imataki; Akihito Matsuoka; Teruhisa Taoka; Kimihiro Kawakami; Toin H van Kuppevelt; Tomoki Todo; Akifumi Takaori-Kondo; Norimitsu Kadowaki

  Molecular therapy : the journal of the American Society of Gene Therapy, 03 Feb. 2021

  
• Development of platelet replacement therapy using human induced pluripotent stem cells.

  Sou Nakamura; Naoshi Sugimoto; Koji Eto

  Development, growth & differentiation, Feb. 2021

  Access this paper :

  
• Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms.

  Maki Oku; Ryo Ishino; Shumpei Uchida; Osamu Imataki; Naoshi Sugimoto; Tomoki Todo; Norimitsu Kadowaki

  British journal of haematology, Jan. 2021

  
• Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.

  Charlotte Flahou; Tatsuya Morishima; Hitoshi Takizawa; Naoshi Sugimoto

  Frontiers in immunology, 2021

  
• Ex vivo generation of platelet products from human iPS cells.

  Sou Nakamura; Naoshi Sugimoto; Koji Eto

  Inflammation and regeneration, 01 Dec. 2020

  
• iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity.

  Daisuke Suzuki; Charlotte Flahou; Norihide Yoshikawa; Ieva Stirblyte; Yoshikazu Hayashi; Akira Sawaguchi; Marina Akasaka; Sou Nakamura; Natsumi Higashi; Huaigeng Xu; Takuya Matsumoto; Kosuke Fujio; Markus G Manz; Akitsu Hotta; Hitoshi Takizawa; Koji Eto; Naoshi Sugimoto

  Stem cell reports, 14 Jan. 2020, Peer-reviewed

  Access this paper :

  
• Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide.

  Kazuyo Yamamoto; Toshio Kitawaki; Naoshi Sugimoto; Haruyuki Fujita; Yumi Kawase; Akifumi Takaori-Kondo; Norimitsu Kadowaki

  Immunology letters, Jul. 2019, Peer-reviewed

  
• αIIbβ3 changes gears in MKs and platelets.

  Naoshi Sugimoto; Koji Eto

  Blood, 18 Apr. 2019, Peer-reviewed

  
• Reconstitution of the hematopoietic system and clinical applications of iPS cells

  杉本直志; 江藤浩之; 江藤浩之

  臨床血液, 2019, Peer-reviewed

  
• A β1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production.

  Hideya Seo; Si Jing Chen; Kazuya Hashimoto; Hiroshi Endo; Yohei Nishi; Akira Ohta; Takuya Yamamoto; Akitsu Hotta; Akira Sawaguchi; Hideki Hayashi; Noritaka Koseki; George J Murphy; Kazuhiko Fukuda; Naoshi Sugimoto; Koji Eto

  Blood advances, 11 Sep. 2018, Peer-reviewed

  
• 新規の物理化学調節機構が1011個の血小板製造を可能にする(Novel physico-chemical regulation mechanism enables to manufacture 1011 order platelets)

  中村 壮; 伊東 幸敬; 杉本 直志; 加藤 好一; 佐久間 臣耶; 伊藤 啓太郎; 公文 広樹; 大野 美紀子; 西 英一郎; 新井 史人; 西村 智; 江藤 浩之

  臨床血液, Sep. 2018

  
• HLAクラスI欠失ヒトiPS細胞由来血小板の抗HLA抗体およびNK細胞に対する免疫逃避(HLA class-I depleted human iPSC-derived platelets evade anti-HLA and NK cell immunity)

  杉本 直志; 鈴木 大助; シャオミン・フェング; 吉川 典秀; 赤坂 まりな; 中村 壮; 遠藤 大; 堀田 秋津; 滝澤 仁; 江藤 浩之

  臨床血液, Sep. 2018, Peer-reviewed

  
• Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production.

  Yukitaka Ito; Sou Nakamura; Naoshi Sugimoto; Tomohiro Shigemori; Yoshikazu Kato; Mikiko Ohno; Shinya Sakuma; Keitaro Ito; Hiroki Kumon; Hidenori Hirose; Haruki Okamoto; Masayuki Nogawa; Mio Iwasaki; Shunsuke Kihara; Kosuke Fujio; Takuya Matsumoto; Natsumi Higashi; Kazuya Hashimoto; Akira Sawaguchi; Ken-Ichi Harimoto; Masato Nakagawa; Takuya Yamamoto; Makoto Handa; Naohide Watanabe; Eiichiro Nishi; Fumihito Arai; Satoshi Nishimura; Koji Eto

  Cell, 26 Jul. 2018, Peer-reviewed

  
• Ex vivo platelet production from induced pluripotent stem cells

  杉本直志; 杉本直志; 江藤浩之; 江藤浩之

  臨床血液, 2018

  
• Selective Inhibition of ADAM17 Efficiently Mediates Glycoprotein Ibα Retention During Ex Vivo Generation of Human Induced Pluripotent Stem Cell-Derived Platelets.

  Shinji Hirata; Takahiko Murata; Daisuke Suzuki; Sou Nakamura; Ryoko Jono-Ohnishi; Hidenori Hirose; Akira Sawaguchi; Satoshi Nishimura; Naoshi Sugimoto; Koji Eto

  Stem cells translational medicine, Mar. 2017, Peer-reviewed

  Access this paper :

  
• Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells.

  Ayako Aihara; Tomo Koike; Natsuki Abe; Sou Nakamura; Akira Sawaguchi; Takanori Nakamura; Naoshi Sugimoto; Hiromitsu Nakauchi; Taito Nishino; Koji Eto

  Blood advances, 28 Feb. 2017, Peer-reviewed

  Access this paper :

  
• Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib

  K-I Ishiyama; T. Kitawaki; N. Sugimoto; T. Sozu; N. Anzai; M. Okada; M. Nohgawa; K. Hatanaka; N. Arima; T. Ishikawa; S. Tabata; T. Onaka; S. Oka; Y. Nakabo; R. Amakawa; M. Matsui; T. Moriguchi; A. Takaori-Kondo; N. Kadowaki

  LEUKEMIA, Jan. 2017, Peer-reviewed

  
• Development of iPS cell-derived blood products and production guidelines.

  Sugimoto N; Eto K

  [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 2017, Peer-reviewed

  
• Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation

  K. Ishiyama; J. Takeda; T. Kondo; N. Sugimoto; H. Kawabata; T. Kitano; A. Takaori-Kondo

  BONE MARROW TRANSPLANTATION, Jul. 2016, Peer-reviewed

  
• Human NLRP3 inflammasome senses multiple types of bacterial RNAs.

  Wenwen Sha; Hiroki Mitoma; Shino Hanabuchi; Musheng Bao; Leiyun Weng; Naoshi Sugimoto; Ying Liu; Zhiqiang Zhang; Jin Zhong; Bing Sun; Yong-Jun Liu

  Proceedings of the National Academy of Sciences of the United States of America, 11 Nov. 2014, Peer-reviewed

  
• Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells.

  Kui Shin Voo; Laura Bover; Megan Lundell Harline; Jinsheng Weng; Naoshi Sugimoto; Yong-Jun Liu

  Journal of immunology (Baltimore, Md. : 1950), 15 Jul. 2014, Peer-reviewed

  
• Helicase proteins DHX29 and RIG-I cosense cytosolic nucleic acids in the human airway system.

  Naoshi Sugimoto; Hiroki Mitoma; Taeil Kim; Shino Hanabuchi; Yong-Jun Liu

  Proceedings of the National Academy of Sciences of the United States of America, 27 May 2014, Peer-reviewed

  
• The DHX33 RNA helicase senses cytosolic RNA and activates the NLRP3 inflammasome.

  Hiroki Mitoma; Shino Hanabuchi; Taeil Kim; Musheng Bao; Zhiqiang Zhang; Naoshi Sugimoto; Yong-Jun Liu

  Immunity, 25 Jul. 2013, Peer-reviewed

  
• Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.

  Hirota K; Yoshitomi H; Hashimoto M; Maeda S; Teradaira S; Sugimoto N; Yamaguchi T; Nomura T; Ito H; Nakamura T; Sakaguchi N; Sakaguchi S

  J Exp Med. 2007 Nov 26;204(12):2803-12., 16 Jul. 2013, Peer-reviewed

  
• miR-22 controls Irf8 mRNA abundance and murine dendritic cell development.

  Haiyan S Li; Nathaniel Greeley; Naoshi Sugimoto; Yong-Jun Liu; Stephanie S Watowich

  PloS one, 2012, Peer-reviewed

  
• Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.

  Keiji Hirota; Hiroyuki Yoshitomi; Motomu Hashimoto; Shinji Maeda; Shin Teradaira; Naoshi Sugimoto; Tomoyuki Yamaguchi; Takashi Nomura; Hiromu Ito; Takashi Nakamura; Noriko Sakaguchi; Shimon Sakaguchi

  The Journal of experimental medicine, 26 Nov. 2007, Peer-reviewed

  
• IgE-activated mast cells in combination with pro-inflammatory factors induce Th2-promoting dendritic cells.

  Toshio Kitawaki; Norimitsu Kadowaki; Naoshi Sugimoto; Naotomo Kambe; Toshiyuki Hori; Yoshiki Miyachi; Tatsutoshi Nakahata; Takashi Uchiyama

  International immunology, Dec. 2006, Peer-reviewed

  
• Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis.

  Naoshi Sugimoto; Takatoku Oida; Keiji Hirota; Kyoko Nakamura; Takashi Nomura; Takashi Uchiyama; Shimon Sakaguchi

  International immunology, Aug. 2006, Peer-reviewed

  
• Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity

  K Kawamura; N Kadowaki; R Suzuki; S Udagawa; S Kasaoka; N Utoguchi; T Kitawaki; N Sugimoto; N Okada; K Maruyama; T Uchiyama

  JOURNAL OF IMMUNOTHERAPY, Mar. 2006, Peer-reviewed

  
• Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab.

  Naoko Watanabe; Takayuki Takahashi; Naoshi Sugimoto; Yasuhiro Tanaka; Masayuki Kurata; Akiko Matsushita; Akinori Maeda; Kenichi Nagai; Kohji Nasu

  International journal of clinical oncology, Oct. 2005, Peer-reviewed

  
• Primary myelofibrosis terminated in basophilic leukemia and successful allogeneic bone marrow transplantation.

  Naoshi Sugimoto; Takayuki Ishikawa; Saori Gotoh; Isaku Shinzato; Akiko Matsushita; Kenichi Nagai; Noriko Ohgoh; Takayuki Takahashi

  International journal of hematology, Aug. 2004, Peer-reviewed

  
• Successful treatment of mu-heavy chain disease with fludarabine monophosphate: A case report

  M Yanai; A Maeda; N Watanabe; N Sugimoto; A Matsushita; K Nagai; T Oida; T Takahashi

  INTERNATIONAL JOURNAL OF HEMATOLOGY, Feb. 2004, Peer-reviewed

  
• Association of intestinal malignant lymphoma and ulcerative colitis

  N Watanabe; N Sugimoto; A Matsushita; A Maeda; K Nagai; K Hanioka; T Takahashi

  INTERNAL MEDICINE, Dec. 2003, Peer-reviewed

  
• Xlim-1 and LIM domain binding protein 1 cooperate with various transcription factors in the regulation of the goosecoid promoter

  T Mochizuki; AA Karavanov; PE Curtiss; KT Ault; N Sugimoto; T Watabe; K Shiokawa; M Jamrich; KWY Cho; IB Dawid; M Taira

  DEVELOPMENTAL BIOLOGY, Aug. 2000, Peer-reviewed

  

Misc.

• Novel platelet pharming using human induced pluripotent stem cells

  C. Flahou; N. Sugimoto; K. Eto

  Bulletin de l'Academie Nationale de Medecine, 01 Dec. 2020

  
• Hydrodynamic mechanism in platelet biogenesis: turbulence enables large-scale platelet production.

  杉本直志; 中村壮; 江藤浩之; 江藤浩之

  月刊血液内科, 2021

  
• 白血病・リンパ腫 iPS細胞を使った血液製剤の開発

  杉本直志; 江藤浩之; 江藤浩之

  Medical Practice, 2020

  
• iPS細胞を用いた血小板製剤の臨床応用の展望

  杉本直志

  血液事業, 2020

  
• Development of large-scale production of highly functional platelets (Turbulence-driven production of iPSC-derived platelets)

  杉本直志; 江藤浩之; 江藤浩之

  実験医学, 2020

  
• がん治療用HSV-1を用いた造血器腫瘍に対するウイルス療法

  石野 亮; 川瀬 有美; 北脇 年雄; 杉本 直志; 稲生 靖; 藤堂 具紀; 高折 晃史; 門脇 則光

  日本がん免疫学会総会プログラム・抄録集, Jul. 2019

  
• iPS細胞を用いた血小板製剤の臨床応用の展望

  杉本直志

  血液事業, 2019

  
• iPS cell-derived platelets

  杉本直志; 江藤浩之; 江藤浩之

  日本内科学会雑誌, 2019

  
• 右心不全を契機に診断された心臓原発悪性リンパ腫の1例

  内田 俊平; 久保 博之; 横倉 繁行; 植村 麻希子; 杉本 直志; 今滝 修; 門脇 則光

  臨床血液, 2019

  
• Environmental Cell-Matrix Adhesion Modulates Pluripotent Stem Cell Fate Toward Definitive Hemogenic Endothelium and Hematopoietic Progenitor Cells

  Akinori Yuzuriha; Sou Nakamura; Toshie Kusunoki; Takuya Matsumoto; Naoshi Sugimoto; Kiyotoshi Sekiguchi; Koji Eto

  BLOOD, Nov. 2018

  
• iPS細胞からの血小板産生

  杉本 直志; 江藤浩之

  臨床血液, Oct. 2018

  
• レナリドミドは骨髄系樹状細胞に作用して抗骨髄腫および抗炎症効果を発揮する(Lenalidomide performs anti-myeloma and anti-inflammatory function through acting on myeloid DCs)

  山本 和代; 北脇 年雄; 杉本 直志; 川瀬 有美; 末木 佑季; 藤田 晴之; 高折 晃史; 門脇 則光

  臨床血液, Sep. 2018

  
• 造血器腫瘍に対するHSV-1ウイルス療法の効果規定因子(A determining factor in efficacy of oncolytic virus therapy with HSV-1 for hematologic malignancies)

  石野 亮; 川瀬 有美; 北脇 年雄; 杉本 直志; 稲生 靖; 藤堂 具紀; 高折 晃史; 門脇 則光

  臨床血液, Sep. 2018

  
• 造血器腫瘍に対するHSV-1ウイルス療法の効果規定因子

  石野 亮; 川瀬 有美; 北脇 年雄; 杉本 直志; 稲生 靖; 藤堂 具紀; 高折 晃史; 門脇 則光

  日本がん免疫学会総会プログラム・抄録集, Jul. 2018

  
• Development of iPSC-derived blood products

  杉本直志; 杉本直志; 江藤浩之; 江藤浩之

  月刊血液内科, 2018

  
• 造血器腫瘍と免疫・凝固系 第2回 造血器腫瘍と免疫療法

  杉本直志; 杉本直志; 門脇則光

  Thrombosis Medicine, 2018

  
• iPS細胞からの血小板製剤の作製

  杉本直志; 杉本直志; 江藤浩之; 江藤浩之

  日本輸血細胞治療学会誌, 2018

  
• iPS細胞由来血小板の品質評価(献血由来血小板との違い)

  渕崎晶弘; 森純平; 越智洋輔; 林智也; 田中光信; 寺田周弘; 寺田あかね; 木村貴文; 谷慶彦; 下垣一成; 高橋順子; 杉本直志; 杉本直志; 中村壮; 清水伸; 江藤浩之; 江藤浩之

  日本輸血細胞治療学会誌, 2018

  
• Platelet production from induced pluripotent stem cells

  N. Sugimoto; K. Eto

  JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Sep. 2017, Peer-reviewed, Invited

  
• iPS血小板は,献血PC製剤とは別物か?

  江藤浩之; 江藤浩之; 中村壮; 清水伸; 杉本直志; 広瀬秀徳; 重盛智大; 伊東幸敬; 西河芳樹; 下垣一成; 下垣一成; 高橋順子; 高橋順子; 木村貴文; 木村貴文; 谷慶彦; 谷慶彦; 寺田周弘; 渡邊直英; 半田誠; 野川誠之

  日本輸血細胞治療学会誌, 2017

  
• NK細胞から見たHLA欠失血小板の有用性と安全性の保証

  鈴木大助; 杉本直志; 吉川典秀; 中村壮; 遠藤大; 堀田秋津; 江藤浩之

  再生医療, 2017

  
• Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib (vol 31, 203, 2017)

  K. Ishiyama; T. Kitawaki; N. Sugimoto; T. Sozu; N. Anzai; M. Okada; M. Nohgawa; K. Hatanaka; N. Arima; T. Ishikawa; S. Tabata; T. Onaka; S. Oka; Y. Nakabo; R. Amakawa; M. Matsui; T. Moriguchi; A. Takaori-Kondo; N. Kadowaki

  LEUKEMIA, Jan. 2017

  
• Current approach of platelet transfusion for regenerative medicine

  鈴木大助; 杉本直志; 江藤浩之

  月刊腎臓内科・泌尿器科, 2017

  
• 造血器腫瘍に対するHSV-1ウイルス療法の開発

  石野 亮; 川瀬 有美; 北脇 年雄; 杉本 直志; 稲生 靖; 藤堂 具紀; 高折 晃史; 門脇 則光

  日本がん免疫学会総会プログラム・抄録集, 2017

  
• Development of iPS cell-derived blood products and production guidelines

  杉本直志; 江藤浩之

  臨床血液, 2017

  
• Innovation of Transfusion Medicine with iPS Cells

  Sugimoto Naoshi; Eto Koji

  Nihon Naika Gakkai Zasshi, 2017

  
• Synthetic miRNA Switch Technology Elucidates Heterogeneity in Regulation of Immortalized Megakaryocyte Cell Lines, Associated with Improvement of Platelet Generation Efficiency for Clinical Use

  Kazuya Hashimoto; Satoshi Matsuura; Yoshihiko Fujita; Karin Hayashi; Naoshi Sugimoto; Takuya Yamamoto; Hirohide Saito; Koji Eto

  BLOOD, Dec. 2016

  
• Natural Killer Cell Activities Against iPSCs-Derived HLA-Knockout Platelets and Megakaryocytes Reveal Perfect Rejection Profiles for Allotransfusion

  Daisuke Suzuki; Naoshi Sugimoto; Norihide Yoshikawa; Hiroshi Endo; Sou Nakamura; Akitsu Hotta; Koji Eto

  BLOOD, Dec. 2016

  
• High-Vorticity with Periodic Flow Enhances in Vitro Biogenesis of Healthy Platelets from iPSC-Derived-Megakaryocytes

  Yukitaka Ito; Sou Nakamura; Tomohiro Shigemori; Naoshi Sugimoto; Yoshikazu Kato; Kazuya Hashimoto; Naohide Watanabe; Masayuki Nogawa; Makoto Handa; Satoshi Nishimura; Koji Eto

  BLOOD, Dec. 2016

  
• Expansion of Dysfunctional CD56-Negative NK Cells Is a Hallmark of NK Cell Activation in Ph+ Leukemia Patients Treated with Dasatinib

  Ken-ichi Ishiyama; Toshio Kitawaki; Naoshi Sugimoto; Akifumi Takaori-Kondo; Norimitsu Kadowaki

  BLOOD, Dec. 2016

  
• 造血器腫瘍に対するHSV-1ウイルス療法の開発

  石野 亮; 川瀬 有美; 北脇 年雄; 杉本 直志; 稲生 靖; 藤堂 具紀; 高折 晃史; 門脇 則光

  日本がん免疫学会総会プログラム・抄録集, Jun. 2016

  
• iPS細胞技術による血小板製剤の開発と臨床試験

  杉本直志; 江藤浩之

  日本臨床, 2016

  
• iPS細胞技術に基づくHLA欠失血小板の作製と実用可能性の検証

  鈴木大助; 杉本直志; 吉川典秀; 中村壮; 遠藤大; 堀田秋津; 江藤浩之

  再生医療, 2016

  
• DUSP4 Stabilizes FOXP3 Expression In Human Regulatory T Cells

  Naoshi Sugimoto; Yong-Jun Liu

  BLOOD, Nov. 2013

  
• Foxp3-expressing regulatory T cells in self-tolerance and autoimmune disease

  S. Sakaguchi; N. Sugimoto; M. Ono; T. Oida; K. Hirota; T. Yamaguchi; T. Nomura

  JOURNAL OF NEUROIMMUNOLOGY, Sep. 2006

  
• 顆粒発達の強い細胞を含むDR陰性AML(M2):2例におけるFlt3ITD検出と3例の塗抹標本形態

  松永恭子; 矢野美由紀; 浄慶幸江; 増田由佳子; 迫田裕之; 炬口真理子; 河野誠司; 熊谷俊一; 西郷勝康; 杉本直志; 永井謙一; 高橋隆幸; 矢部博樹; 近藤信一; 稲葉亨; 岡本茂高; 古田香穂; シアンプルナワチ メイラニ; 巽英二

  日本検査血液学会雑誌, 2006

  
• 活性化ヒト肥満細胞による単球由来樹状細胞の成熟とTh2反応の誘導

  北脇 年雄; 門脇 則光; 杉本 直志; 神戸 直智; 宮地 良樹; 内山 卓

  日本血液学会・日本臨床血液学会総会プログラム・抄録集, Sep. 2005

  
• 活性化ヒト肥満細胞による単球由来樹状細胞の成熟とTh2反応の誘導

  北脇 年雄; 門脇 則光; 杉本 直志; 神戸 直智; 宮地 良樹; 内山 卓

  日本リンパ網内系学会会誌, Jun. 2005

  
• ヒト肥満細胞による樹状細胞の活性化とT細胞反応への影響

  北脇 年雄; 杉本 直志; 門脇 則光; 神戸 直智; 内山 卓

  日本免疫学会総会・学術集会記録, Nov. 2004

  
• 複数以上のHLA座不一致の造血幹細胞移植

  一戸辰夫; 杉本直志; 内山卓

  臨床病理レビュー特集, 2002

  
• 血球どん食症候群を合併した重症急性すい炎の1例

  西馬信一; 杉本直志; 高橋健; 木本直哉; 上嶋一臣; 岡田明彦; 岡部純弘; 樫田博史; 小西豊

  日本消化器病学会雑誌, 2001

  
• IgA-λ型M蛋白血症と胸腺腫りゅうを伴ったlymphoplasmacytoid lymphomaの一例

  永井謙一; 杉本直志; 松下章子; 前田明則; 高橋隆幸; 浜野照明

  臨床血液, 2001

  
• t(3;21)(q26;q22)転座を有した2次性急性骨髄性白血病の一例

  杉本直志; 松下章子; 前田明則; 永井謙一; 高橋隆幸

  International Journal of Hematology. Supplement, 2001

  
• よう虫病の1例

  大郷典子; 菅野優子; 藤井公男; 杉本直志

  皮膚, 2000

  
• AML-M3様の形態を示した,AML-M2の一例

  杉本直志; 松下章子; 前田明則; 永井謙一; 高橋隆幸; 巽英二

  臨床血液, 2000

  
• 再発の度にlow dose Ara-Cが有効で,7回の完全寛解が得られたAML-M2の一症例

  松下章子; 杉本直志; 前田明則; 永井謙一; 高橋隆幸

  臨床血液, 2000

  
• cryoglobulinの性格を有するIgG-κ型骨髄腫の一例

  永井謙一; 中山志郎; 杉本直志; 松下章子; 前田明則; 高橋隆幸

  臨床血液, 2000

  

Presentations

• iPS細胞技術を用いた造血システムの再構成と治療への応用

  杉本直志

  第81回日本血液学会学術集会, 11 Oct. 2019, Invited

  
• iPS細胞を用いた血小板製剤の臨床応用の展望

  杉本直志

  第４３回日本血液事業学会, 02 Oct. 2019, Invited

  
• Turbulence enables large scale production and clinical application of iPS cell-derived platelets

  Naoshi Sugimoto

  第17回先端血液学セミナー, 08 Jun. 2019, Invited

  
• iPS血小板の開発と臨床応用

  杉本直志

  第18回先端医療フォーラム, 31 May 2019, Invited

  
• iPS細胞由来血小板製剤の開発と将来

  杉本直志

  第50回日赤薬剤師会血液センター研究会, 10 Mar. 2019, Invited

  
• Environmental Cell-Matrix Adhesion Modulates Pluripotent Stem Cell Fate toward Definitive Hemogenic Endothelium and Hematopoietic Progenitor Cells

  Akinori Yuzuriha; Sou Nakamura; Toshie Kusunoki; Takuya Matsumoto; Naoshi Sugimoto; Kiyotoshi Sekiguchi; Koji Eto

  60th American Society of Hematology Annual Meeting and Exposition, 01 Dec. 2018

  
• iPS血小板の臨床応用に向けて

  杉本直志

  第110回近畿血液学地方会, 10 Nov. 2018, Invited

  
• HLA クラスI欠失ヒトiPS細胞由来血小板の抗HLA抗体およびNK細胞に対する免疫逃避

  杉本直志; 鈴木大助; シャオミン・フェング; 吉川典秀; 赤坂まりな; 中村壮; 遠藤大; 堀田秋津; 滝澤仁; 江藤 浩之

  第80回日本血液学会学術集会, 14 Oct. 2018

  
• iPS細胞からの血小板産生

  杉本直志; 江藤浩之

  第80回日本血液学会学術集会, 14 Oct. 2018, Invited

  
• 新規の物理化学調節機構が1011個の血小板製造を可能にする

  中村壮; 伊東幸敬; 杉本直志; 加藤好一; 佐久間臣耶; 伊藤啓太郎; 公文広樹; 大野美紀子; 西英一郎; 新井史人; 西村智; 江藤浩之

  第80回日本血液学会学術集会, 13 Oct. 2018

  
• レナリドミドは骨髄系樹状細胞に作用して抗骨髄腫および抗炎症作用を発揮する

  山本和代; 北脇年雄; 杉本直志; 川瀬有美; 末木佑季; 藤田晴之; 高折晃史; 門脇則光

  12 Oct. 2018

  
• 造血器腫瘍に対するHSV-1ウイルス療法の効果規定因子

  石野亮; 川瀬有美; 北脇年雄; 杉本直志; 稲生靖; 藤堂具紀; 高折晃史; 門脇則光

  12 Oct. 2018

  
• A novel β1-tubulin-based megakaryocyte reporter system identifies compounds that promote megakaryocyte maturation and platelet production

  Chen SJ; Seo H; Hotta A; Nishi Y; Ohta A; Hayashi H; Sugimoto N; Eto K

  23rd Congress of European Hematology Association Meeting, 14 Jun. 2018

  
• iPS細胞からの血小板の作製

  杉本直志; 江藤浩之

  第66回日本輸血・細胞治療学会総会, 25 May 2018, Invited

  
• HLA gene knockout in human iPS cells: a tool in developing versatile cellular regenerative therapy

  Naoshi Sugimoto

  第26回日本組織適合性学会大会, 28 Oct. 2017, Invited

  
• iPS細胞を用いた血液製剤の開発と法整備

  杉本直志; 江藤浩之

  第79回日本血液学会学術集会, 21 Oct. 2017, Invited

  
• Allogenic hematopoietic stem cell transplantations of the elderly at Kyoto University Hospital

  杉本 直志; 近藤 忠一; 菱澤 方勝; 北野 俊行; 高折-近藤 晃史

  第77回日本血液学会学術集会, Oct. 2015

  
• Helicase Proteins DHX29 and RIG-I Cosense Cytosolic Nucleic Acids in the Human Airway System

  Naoshi Sugimoto

  口演（Best Presentation Award）、第43回日本免疫学会学術集会(2014), Kyoto, Dec. 2014

  
• ヘリカーゼ・タンパクDHX29とRIG-Iによるヒト気道組織のウィルス/核酸の細胞質内センシングとサイトカイン産生

  杉本 直志

  招待講演、第10回感染症サイトカイン研究会 （2014）、 神戸, 2014, Invited

  
• DUSP4 Stabilizes FOXP3 Expression In Human Regulatory T Cells

  Naoshi Sugimoto

  55th Annual Meeting of the American Society of Hematology (2013), New Orleans, Dec. 2013

  
• TGFβによるナイーブCD4+T細胞のFoxp3遺伝子発現誘導の定量的解析

  杉本 直志

  第34回日本免疫学会総会 (2004), 2004

  
• 高度の好塩基球増多を呈し同種骨髄移植にて軽快した原発性骨髄線維症の一例

  杉本 直志; 石川隆之; 後藤さおり; 新里偉咲; 松下章子; 永井謙一; 高橋隆幸; 内田博也; 大郷典子

  第60回日本血液学会学術集会, Mar. 1998

  
• Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis

  Naoshi Sugimoto

  第36回日本免疫学会学術集会 (2006), Osaka

  
• 細胞質核酸センサーによる感染防御とその臨床的意義

  杉本 直志

  招待講演、第3回京都血液フォーラム （2015）

  

Books and Other Publications

• ハリソン内科学

  杉本 直志, Joint translation, 第4章 再生医療; 幹細胞生物学

  2017, Not refereed

  

External funds: Kakenhi

• Elucidation of the NK cell immune escape mechanism using iPS cell-derived platelets and development of treatment

  Grant-in-Aid for Scientific Research (C)

  Basic Section 54010:Hematology and medical oncology-related

  Kyoto University

  Naoshi Sugimoto

  From 01 Apr. 2021, To 31 Mar. 2024, Project Closed

  iPS細胞;血小板;HLAクラスI;遺伝子編集;NK細胞;TGF-β;ヒト化マウス;TGFβ;プロテオミック解析;免疫抑制分子;ライブ動態解析;HLA;免疫寛容

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21K08413/
• Elucidating the fundamental mechanism of platelet biogenesis and its medical application

  Grant-in-Aid for Scientific Research (S)

  Broad Section I

  Kyoto University

  江藤 浩之

  From 05 Jul. 2021, To 31 Mar. 2026, Granted

  造血システム;血小板;乱流;バイオリアクター;iPS細胞;脂質膜;巨核球;培養槽

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21H05047/
• The role of the nucleic acid sensor molecule DHX29 in hematopoietic cell immune responses and hematopoietic tumors

  Grant-in-Aid for Scientific Research (C)

  Kagawa University;Kyoto University

  Naoshi Sugimoto

  From 01 Apr. 2015, To 31 Mar. 2019, Project Closed

  DHX29;DDX41;造血器腫瘍;細胞内核酸センサー;eIF4E;eIF4GI;eIF4F;細胞質内核酸センサー;血液細胞;核酸センシング;自然免疫;造腫瘍性

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K09500/

Administration

Faculty management (title, position)

• From 01 Apr. 2025, To 31 Mar. 2027

  安全衛生委員会

Academic, Social Contribution

Academic Contribution

• iPS細胞から輸血用の血小板を作る

  京都大学, From 30 Sep. 2017

  
• iPS細胞技術を基盤とする血小板製剤の開発と臨床試験

  京都大学, From 18 Sep. 2016